Emerging medicinal use On 1 July, 2023, the Therapeutic Goods Administration amended its scheduling of copyright substances to allow the prescription of psilocybin to be used in copyright assisted psychotherapy for treatment-resistant melancholy. Trials as to their usefulness and basic safety in managing a variety of psychiatric ailments are ongoi